Belantamab + Cevostamab + Pomalidomide for Multiple Myeloma

Belamaf + Cevostamab at RP2D with pomalidomide at 2 mg at 14/21 schedule in cycles: induction phase cycles are 21 days (Q3W) for 6 cycles followed by maintenance phase cycles, which are are 42 days (Q6W). pomalidomide on 14/21 schedule. Treatment will continue until progression or unacceptable toxicity.

Belamaf + Cevostamab will be administrated on the dose escalation schedule in cycles: induction phase cycles are 21 days (Q3W) for 6 cycles followed by maintenance phase cycles, which are 42 days (Q6W). Up to 3 cohorts (Cohorts 1a-c) evaluating escalating doses of belamaf and cevostamab will be evaluated. (Cohort 1a - belamaf 1.9 mg/kg + cevostamab 90 mg; Cohort 1b - belamaf 1.9 mg/kg + cevostamab 160 mg; and Cohort 1c - belamaf 2.5 mg/kg + cevostamab 160 mg.) Treatment will continue until progression or unacceptable toxicity. Then, after the recommended phase 2 dose (RP2D) is determined, Cohort 2 will receive Belamaf + Cevostamab at the RP2D schedule in cycles: induction phase cycles are 21 days (Q3W) for 6 cycles followed by maintenance phase cycles, which are 42 days (Q6W). Treatment will continue until progression or unacceptable toxicity.